Vium showcases new research suite advances at this year’s American Association for Laboratory Animal Science Conference in Denver, CO
October 8, 2019
San Mateo, CA — Vium, Inc. www.vium.com, the scientific leader in delivering digital biomarker driven insights from preclinical in vivo research, will attend the American Association for Laboratory Animal Science (AALAS) conference at the Colorado Convention Center in Denver from October 13-17, 2019 (Booth # 887). At the conference Vium will be showcasing the newest features for its Vium Smart Housing™ System including animal health alerting and data visualization.
“Ensuring animal welfare is a central tenant to the collection of quality scientific data,” said Laura Schaevitz, CSO of Vium. “Traditionally, researchers are limited in the data that can be collected from each animal on study. The Vium platform is fundamentally changing that paradigm. Digital biomarker data are collected continuously on each animal throughout the study with the goal of using these large data sets to create algorithms that more reliably and accurately predict disease and compound efficacy. Early on, we realized that unexpected mortality was a huge challenge that could serve as an initial testing ground and our attention turned to creating algorithms to identify unhealthy animals. The release of automated health alerting is a great example of how Vium can use the rich digital biomarker data sets to build algorithms to predict disease state in an animal.”
The state-of-the-art platform, including Vium’s Smart Housing™, Vium Cloud, and Research Suite is the gold-standard in vivo platform combining computer vision, artificial intelligence (AI), machine learning (ML) and sensor technology to non-invasively collect digital biomarkers from the animal in its home cage. These digital biomarkers include data on animal activity levels, breathing rate, and other behaviors. By providing continuous, rich data sets, the platform enables researchers to identify which digital biomarkers, or combinations of biomarkers, are the strongest indicators in a specific disease model. Currently, Vium, in collaboration with pharma, biotech, and academic partners, have explored digital signatures of more than 40 different animal models of disease.
“Vium’s Smart housing™ system is now installed at 5 of the top 10 global pharmaceutical companies,” said Ted Ira, Vice President of Sales for Vium. “We are excited to be at this year’s AALAS conference to show how leading Pharmaceutical and Biotech research innovators are benefiting from the Vium platform to advance animal welfare and improve in vivo research results.”
The focus of this year’s AALAS conference Spotlight Forum is, “One Health–Connections Between Animal, Human, and Environmental Health”. The concept recognizes that the health of people is connected to the health of animals and the environment. The forum will bring together veterinarians, physicians, ecologists, and many others to learn from each other and learn how disease spreads among people, animals, and the environment.
“Vium is as committed to animal welfare as we are to bringing innovative technology to drug development,” said Wendel Barr, CEO of Vium. “In collaboration with large pharmaceutical and biotech clients, Vium is making rapid progress in adding new digital biomarkers and analytics capabilities to the platform to further improve the reproducibility and predictive power of animal models.”
Leveraging AI and digital sensors to replace manual monitoring improves the quality and reliability of data, while at the same time reducing stress on the animal, which can also impact experimental results. It also allows researchers the ability to collect more data than is possible using manual methods. Vium is the frontrunner in developing a full stack solution that includes hardware, software and scientific insights.
About Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible. Vium is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the ‘3 Rs’, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical and computational drug discovery companies, academia, and novel therapeutic labs. Vium is backed by leading investors, including Lux Capital, Data Collective, Dolby Family Ventures, AME Cloud Ventures, Founders Fund, and Future Shape LLC. Vium is headquartered in San Mateo, California. Visit Vium at www.vium.com.